Rupa Mazumder

1.3k citations

140 papers · 937 indexed · h-index 15

Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems 18
- Drug Solubulity and Delivery Systems 12
- Advancements in Transdermal Drug Delivery 12
Pharmacology top 5%
Complementary and alternative medicine top 5%
Organic Chemistry top 10%
- Synthesis and biological activity 16
Food Science top 10%
- Essential Oils and Antimicrobial Activity 10
Computational Theory and Mathematics
- Computational Drug Discovery Methods 16
Endocrinology, Diabetes and Metabolism
- Natural Antidiabetic Agents Studies 10
Plant Science
- Phytochemistry and Biological Activities 10

Co-authors: Avijit Mazumder Sujata G. Dastidar Salahuddin Salahuddin Amrish Chandra Seema Garg Mohamed Jawed Ahsan Mohammad Shahar Yar Priya Gupta
Cited by: Pharmaceutical Science Pharmacology Complementary and alternative medicine
Partner nations: India Nepal Saudi Arabia

In The Last Decade

Rupa Mazumder

118 papers receiving 856 citations

Peers

Countries citing papers authored by Rupa Mazumder

Since Specialization

Citations

This map shows the geographic impact of Rupa Mazumder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rupa Mazumder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rupa Mazumder more than expected).

Fields of papers citing papers by Rupa Mazumder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rupa Mazumder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rupa Mazumder. The network helps show where Rupa Mazumder may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rupa Mazumder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rupa Mazumder Line = papers co-authored together Rupa Mazumder links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Challenges and Progress of Orphan Drug Development for Rare Diseases Abhijit Debnath,Rupa Mazumder,(unknown),Pankaj Tyagi,Rajesh Kumar Singh	2025	0
2	Revolutionizing Skin Cancer Treatment: The Rise of PD-1/PDL-1 and CTLA-4 as Key Therapeutic Targets Neha Sharma,Rupa Mazumder,Pallavi Rai	2024	2
3	Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes Saloni Mangal,Abhijit Debnath,Rupa Mazumder,Avijit Mazumder,Rajesh Kumar Singh,Jahanvi Sanchitra,Stephen Jan,Pratibha Pandey,Bimlesh Kumar,Anil Kumar Singh	2024	1
4	GASTRORENTENTIVE HYDROGELS RESPONSIVE TO EXTERNAL STIMULI FOR NOVEL DRUG DELIVERY GAURAV MORIYA,Rupa Mazumder,SWARUPANJALI PADHI,Rakhi Mishra	2024	1
5	Insight into the Various Synthetic Approaches of 1,3,4 and 1,2,4- Oxadiazole and its Derivatives, along with their Remarkable Biological Activities Sadhana Sharma,Chandana Majee,Rupa Mazumder,Kavita Rana,Sanghamitra Padhi,Avijit Mazumder,Saumya Das,Pankaj Kumar Taygi,Sachin Kumar Singh	2024	1
6	Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review Abhijit Debnath,Rupa Mazumder	2024	5
7	Discovery of novel CDK4/6 inhibitors from fungal secondary metabolites Abhijit Debnath,Rupa Mazumder,Rajesh Kumar Singh,Anil Kumar Singh	2024	5
8	Identification of Novel CDK 4/6 Inhibitors by High-throughput Virtual Screening Abhijit Debnath,Rupa Mazumder	2024	4
9	REVIEW OF SARS-CORONAVIRUS-2 REPERCUSSIONS ON THYROID GLAND IN THE CONTEXT OF HYPERTHYROIDISM S V Singh,Monika,Rupa Mazumder,Avijit Mazumder	2023	0
10	Development in therapeutic strategies for allergic conjunctivitis Neha Singh,Rupa Mazumder,Monika Monika,Sakshi Sakshi,Fahad Khan,Bimlesh Kumar	2023	0
11	Novel approaches for allergen-specific immunotherapy—An overview Sakshi Sakshi,Rupa Mazumder,Monika Monika,Neha Singh,Bimlesh Kumar	2023	1
12	Ophthalmic Drug Delivery: New Dimensions RAJAT BUDHORI,Rupa Mazumder,Rakhi Mishra,AYUSHI KAUSHIK,MANORMA,SWARUPANJALI PADHI	2023	0
13	Multifaceted Understandings of Cancer: A Review of Disease Mechanisms and Therapies Rashmi Saxena Pal,Yogendra Pal,MVNL Chaitanya,Ravindra Babu,Rupa Mazumder,Arvind Kumar	2023	1
14	Preformulation screening of lipids using solubility parameter concept in conjunction with experimental research to develop ceftriaxone loaded nanostructured lipid carriers Swarupanjali Padhi,Rupa Mazumder,Shradha Bisht	2023	7
15	PD 1: A Trending Target in Anti-cancer Research Shweta Rani,Rupa Mazumder,Neha Sharma,Rakhi Mishra,Abhijit Debnath,Swarnali Das,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2022	2
16	Insights into Interactions of Human Cytochrome P450 17A1: A Review Himanshu Singh,Rajnish Kumar,Avijit Mazumder,Salahuddin Salahuddin,Rupa Mazumder,Mohd Mustaqeem	2022	11
17	Potential of Nanotechnology-based Formulations in Combating PulmonaryInfectious Diseases: A Current Scenario Manisha Patel,Rupa Mazumder,Rakhi Mishra,Kamal Kant Kaushik	2022	2
18	Efficient Green Synthesis and Biological Evaluation of Thiadiazole Derivatives Prem Shankar Mishra,Rakhi Mishra,Ram B. Gupta,Rupa Mazumder,Rishabha Malviya,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2021	2
19	An Updated Review on Synthesis and Biological Activities of Thiosemicarbazide Analogs Akhalesh Kumar,Rakhi Mishra,Avijit Mazumder,Rupa Mazumder,Arun Kumar	2021	1
20	In Vitro Anti-Fungal Activity of the Methanolic Extract of the Leaves Lagerstroemia parviflora (Roxb.) Sangita Kumari,Avijit Mazumder,Rupa Mazumder,Shilpa Pahwa	2010	1

About Rupa Mazumder

Rupa Mazumder is a scholar working on Pharmaceutical Science, Pharmacology and Applied Microbiology and Biotechnology, having authored 140 papers that have together received 937 indexed citations. Recurring topics across this work include Advanced Drug Delivery Systems (18 papers), Synthesis and biological activity (16 papers), Computational Drug Discovery Methods (16 papers), Drug Solubulity and Delivery Systems (12 papers), Advancements in Transdermal Drug Delivery (12 papers), Natural Antidiabetic Agents Studies (10 papers), Phytochemistry and Biological Activities (10 papers) and Essential Oils and Antimicrobial Activity (10 papers). The work is most often cited by research in Pharmaceutical Science (102 citations), Pharmacology (129 citations) and Complementary and alternative medicine (96 citations). Rupa Mazumder has collaborated with scholars based in India, Nepal and Saudi Arabia. Frequent co-authors include Avijit Mazumder, Sujata G. Dastidar, Salahuddin Salahuddin, Amrish Chandra, Seema Garg, Mohamed Jawed Ahsan, Mohammad Shahar Yar, Priya Gupta, Rakhi Mishra and Subhra Bhattacharya.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact